Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1994-11-4
|
pubmed:abstractText |
Oral oestrogen treatment in postmenopausal women causes a decrease of insulin-like growth factor I (IGF-I) serum level, probably through a hepatocellular effect. To explore the possibility that the androgenic progestogens oppose this effect, serum IGF-I and sex hormone binding globulin (SHBG) were evaluated in two groups of patients treated respectively with oral conjugated oestrogens (oCE) or transdermal oestradiol (tdE2), in a first phase with the addition of dydrogesterone (DYDR), a non-androgenic progestogen, and subsequently with the addition of norethisterone acetate (NETA). With respect to basal values, treatment with oCE+DYDR caused an increase of SHBG (P < 0.002) and a decrease of IGF-I serum levels (P < 0.05); the shift to NETA addition opposed both effects: SHBG levels decreased partially but significantly (P < 0.01 vs. oCE + DYDR) and IGF-I returned to basal values with a significant increase with respect to the oCE + DYDR phase (P < 0.02). No changes were observed in the tdE2 + DYDR treated women; in this group the shift to NETA addition caused a significant decrease of SHBG values (P < 0.001 vs. before treatment and vs. tdE2 + DYDR phase) and a slight increase of IGF-I values. These differential effects on IGF-I and SHBG serum levels might be relevant as far as breast cancer risk is concerned.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dydrogesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens, Conjugated (USP),
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Norethindrone,
http://linkedlifedata.com/resource/pubmed/chemical/Sex Hormone-Binding Globulin,
http://linkedlifedata.com/resource/pubmed/chemical/norethindrone acetate
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0378-5122
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
25-31
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7935029-Administration, Cutaneous,
pubmed-meshheading:7935029-Administration, Oral,
pubmed-meshheading:7935029-Adult,
pubmed-meshheading:7935029-Breast Neoplasms,
pubmed-meshheading:7935029-Climacteric,
pubmed-meshheading:7935029-Drug Therapy, Combination,
pubmed-meshheading:7935029-Dydrogesterone,
pubmed-meshheading:7935029-Estradiol,
pubmed-meshheading:7935029-Estrogen Replacement Therapy,
pubmed-meshheading:7935029-Estrogens, Conjugated (USP),
pubmed-meshheading:7935029-Female,
pubmed-meshheading:7935029-Humans,
pubmed-meshheading:7935029-Insulin-Like Growth Factor I,
pubmed-meshheading:7935029-Middle Aged,
pubmed-meshheading:7935029-Norethindrone,
pubmed-meshheading:7935029-Risk Factors,
pubmed-meshheading:7935029-Sex Hormone-Binding Globulin
|
pubmed:year |
1994
|
pubmed:articleTitle |
Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
|
pubmed:affiliation |
Department of Endocrinologic Gynaecology, St. Anna Hospital, Turin, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|